公开(公告)号：USPP32003P2

公开(公告)日：2020-07-21

申请号：US16350990

申请日：2019-02-08

申请人： The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Don R. LaBonte

IPC分类号： A01H5/12 ,  A01H6/00

摘要： A new variety of sweetpotato, identified as ‘LA17-54’, is disclosed having disease resistance to Fusarium wilt; an orange flesh, red-copper skin storage root and attractive purple, red-hued and green leaves with purple venation and purple vines.

公开(公告)号：USPP31970P2

公开(公告)日：2020-07-14

申请号：US16350984

申请日：2019-02-08

申请人： The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Don R. LaBonte ,  Arthur Q. Villordon ,  Christopher A. Clark

IPC分类号： A01H5/06 ,  A01H6/00

摘要： A new variety of sweetpotato, identified as ‘LA08-21P’, is disclosed having resistance to both Fusarium wilt and southern root knot nematode; a light purple-banded flesh and deep-purple skin, and moderately high yield characteristics.

公开(公告)号：USPP31969P2

公开(公告)日：2020-07-14

申请号：US16350987

申请日：2019-02-08

申请人： The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Don R. LaBonte

IPC分类号： A01H5/06 ,  A01H6/00

摘要： A new variety of sweetpotato, identified as ‘LA17-40’, is disclosed having resistance to southern root-knot nematode; an orange flesh and attractive 5 lobed dark green and purple leaves.

公开(公告)号：US10190955B2

公开(公告)日：2019-01-29

申请号：US14937634

申请日：2015-11-10

申请人： California Institute of Technology ,  The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Md. Zubaer Hossain ,  Chun-Jen Hsueh ,  Kaushik Bhattacharya ,  Guruswami Ravichandran ,  Blaise Aurélien Bourdin

IPC分类号： G01N3/40 ,  G01N3/08

摘要： Systems and methods in accordance with embodiments of the invention determine the effective toughness of a given material, and also implement materials possessing improved effective toughness values. In one embodiment, a method of determining the effective toughness of a material includes: causing a crack to propagate through the material; where the relative constant velocity and the relative overall direction are prescribed and maintained for the duration of the propagation of the crack through the material; measuring the energy release rate of the crack as it propagates through the material; and defining the effective toughness of the material as the maximum value of the measured energy release rate.

公开(公告)号：US09700578B2

公开(公告)日：2017-07-11

申请号：US14589324

申请日：2015-01-05

申请人： The United States of America as represented by the Secretary of the Department of Health and Human Services ,  The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Acting through Louisiana State University Health Sciences Center ,  The UAB Research Foundation ,  Loma Linda University ,  Wake Forest University

发明人： Mark T. Gladwin ,  Alan N. Schechter ,  David J. Lefer ,  Rakesh P. Patel ,  Christian J. Hunter ,  Gordon G. Power ,  Daniel B. Kim-Shapiro ,  Ryszard Marek Pluta ,  Edward H. Oldfield ,  Richard O. Cannon, III

IPC分类号： A61K33/00 ,  A61K45/06

CPC分类号： A61K33/00 ,  A61K45/06 ,  A61K2300/00

摘要： It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

公开(公告)号：US09675637B2

公开(公告)日：2017-06-13

申请号：US10563683

申请日：2004-07-09

申请人： Mark T. Gladwin ,  Alan N. Schechter ,  David J. Lefer ,  Rakesh P. Patel ,  Christian J. Hunter ,  Gordon G. Power ,  Daniel B. Kim-Shapiro ,  Ryszard Pluta ,  Edward H. Oldfield ,  Richard O. Cannon, III

发明人： Mark T. Gladwin ,  Alan N. Schechter ,  David J. Lefer ,  Rakesh P. Patel ,  Christian J. Hunter ,  Gordon G. Power ,  Daniel B. Kim-Shapiro ,  Ryszard Pluta ,  Edward H. Oldfield ,  Richard O. Cannon, III

IPC分类号： A61K45/06 ,  A61K33/00

CPC分类号： A61K33/00 ,  A61K45/06 ,  A61K2300/00

摘要： It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

公开(公告)号：US09034347B2

公开(公告)日：2015-05-19

申请号：US13720157

申请日：2012-12-19

申请人： Aphios Corporation

发明人： Trevor Percival Castor ,  Jonathan Steven Alexander ,  Geoffrey Purdum ,  J. David Rios ,  Lisa M. Schrott ,  Theodore A. Tyler ,  Maria I. Vizcaino

IPC分类号： A61K9/16 ,  A61K9/48 ,  A61K9/51 ,  A61K31/365

CPC分类号： A61K9/5153 ,  A61K9/16 ,  A61K9/4858 ,  A61K31/365

摘要： Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.

摘要翻译： 本发明的实施方案涉及用于治疗神经退行性疾病的苔藓抑素的口服给药。

公开(公告)号：US20120201907A1

公开(公告)日：2012-08-09

申请号：US13446700

申请日：2012-04-13

申请人： David A. WINK ,  Martin FEELISCH ,  David A. KASS ,  Nazareno PAOLOCCI ,  Katrina MIRANDA ,  Jon FUKUTO ,  Tatsuo KATORI

发明人： David A. WINK ,  Martin FEELISCH ,  David A. KASS ,  Nazareno PAOLOCCI ,  Katrina MIRANDA ,  Jon FUKUTO ,  Tatsuo KATORI

IPC分类号： A61K33/00 ,  A61P9/04 ,  A61K31/131

CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

摘要翻译： 施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。 此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。 另外，与使用NO供体观察到的效果相反，将HNO / NO供体与正性肌力药物组合给药不会损害正性肌力药物的正性肌力作用。 此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

公开(公告)号：US08071364B2

公开(公告)日：2011-12-06

申请号：US10583812

申请日：2004-12-24

申请人： Richard Cooper ,  Frederick M. Enright ,  William C. Fioretti

发明人： Richard Cooper ,  Frederick M. Enright ,  William C. Fioretti

IPC分类号： C12N5/00 ,  C12N15/00 ,  C07H21/02 ,  C07H21/04 ,  C07K2/00

CPC分类号： C12N15/8509 ,  A61K48/00 ,  C12N2800/107 ,  C12N2800/90

摘要： Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.

摘要翻译： 呈现方法和组合物用于向动物或人施用基于转座子的载体，以向动物或人提供基因治疗。

公开(公告)号：US20050192254A1

公开(公告)日：2005-09-01

申请号：US11096924

申请日：2005-03-31

申请人： David Wink ,  Martin Feelisch ,  David Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

发明人： David Wink ,  Martin Feelisch ,  David Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

IPC分类号： A61K31/13 ,  A61K31/16 ,  A61K31/655 ,  A61K31/137

CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO+ donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

摘要翻译： 施用HNO / NO - 辅助化合物，例如Angeli盐，增加心肌收缩力，同时降低经历心力衰竭的受试者的左心室预负荷。 此外，给予HNO / NO - 供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO ）令人惊讶地在经历心力衰竭的受试者中表现出正向的变力作用，其优于由提供HNO /供体化合物Angeli盐引起的那些。 另外，与使用NO + +供体观察到的效果相反，与正性肌力药物组合施用HNO / NO + - 供体不会损害正性肌力作用 正性肌力药。 此外，HNO / NO 发挥其与肾上腺素能系统无关的正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也增加收缩力。